Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
Holi-to-Holi multibaggers: From market favourites to hidden gems, 80 stocks deliver up to 1,822% returns
Ahead of Holi 2026, several Indian stocks have emerged as multibaggers since last Holi, delivering exceptional returns despite market volatility. While strong performers span sectors